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ABSTRACT
Background
Development of new, effective, and affordable tuberculosis (TB) therapies has been identified
as a critical priority for global TB control. As new candidates emerge from the global TB drug
pipeline, the potential impacts of novel, shorter regimens on TB incidence and mortality have
not yet been examined.
Methods and Findings
We used a mathematical model of TB to evaluate the expected benefits of shortening the
duration of effective chemotherapy for active pulmonary TB. First, we considered general
relationships between treatment duration and TB dynamics. Next, as a specific example, we
calibrated the model to reflect the current situation in the South-East Asia region. We found
that even with continued and rapid progress in scaling up the World Health Organization’s
DOTS strategy of directly observed, short-course chemotherapy, the benefits of reducing
treatment duration would be substantial. Compared to a baseline of continuing DOTS coverage
at current levels, and with currently available tools, a 2-mo regimen introduced by 2012 could
prevent around 20% (range 13%–28%) of new cases and 25% (range 19%–29%) of TB deaths in
South-East Asia between 2012 and 2030. If effective treatment with existing drugs expands
rapidly, overall incremental benefits of shorter regimens would be lower, but would remain
considerable (13% [range 8%–19%] and 19% [range 15%–23%] reductions in incidence and
mortality, respectively, between 2012 and 2030). A ten-year delay in the introduction of new
drugs would erase nearly three-fourths of the total expected benefits in this region through
2030.
Conclusions
The introduction of new, shorter treatment regimens could dramatically accelerate the
reductions in TB incidence and mortality that are expected under current regimens—with up to
2- or 3-fold increases in rates of decline if shorter regimens are accompanied by enhanced case
detection. Continued progress in reducing the global TB burden will require a balanced
approach to pursuing new technologies while promoting wider implementation of proven
strategies.
The Editors’ Summary of this article follows the references.
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Tuberculosis (TB) persists as a leading global cause of
death. In 2003, nearly 9 million new cases of active pulmonary
TB and 2 million deaths from TB were reported [1]. After
major and sustained progress in reducing the burden of TB—
marked by declines for over a century in some industrialized
countries [2–4]—global TB control efforts have faced new
challenges due to the HIV epidemic and the rise of drug
resistance in several settings [5,6].
Following the Millennium Declaration, endorsed by con-
sensus of the members of the United Nations [7], targets
relating to global TB control have been guided by the
Millennium Development Goals—speciﬁcally, the aim of
having ‘‘halted by 2015 and begun to reverse the incidence
of malaria and other major diseases’’ [8]. Extending this
objective to include other indicators of progress against TB
beyond reductions in incidence, the Stop TB partnership
further resolved to halve TB prevalence and death rates
between 1990 and 2015 [9].
The cornerstone of global TB control efforts led by the
World Health Organization (WHO) is the DOTS strategy,
which relies on short-course chemotherapy for individuals
with active pulmonary TB, with drugs administered under the
direct observation of health workers. Case detection in DOTS
is based on identifying individuals who present to health
services with persistent cough, and screening them by
examination of sputum smears. Cure rates above 80% have
been achieved using DOTS [1], but concerns have been raised
about the scope and pace of DOTS expansion and potential
limits to the reach of passive case detection under DOTS [10].
Current standardized regimens for treating TB require four
or more drugs administered for at least six months [11]. No
new ﬁrst-line TB drugs have been developed in over 30 years.
Shorter regimens including novel drugs have the potential to
advance TB control efforts by speeding treatment comple-
tion—thereby limiting opportunities for default and the
potential emergence of drug resistance—and reducing relapse
rates. Shorter regimens may also facilitate expanded case-
detection efforts by freeing scarce resources and lowering
patient-related barriers to initiating therapy. These effects
would be expected to translate directly into better outcomes
for those receiving treatment, and indirectly into lower TB
incidence and mortality due to reduced transmission.
As new drug candidates emerge from the global TB drug
pipeline [12], the potential exists to modify or replace
existing regimens with faster-acting drugs that could reduce
treatment time, work concomitantly with HIV therapies, and
overcome multidrug resistance. An array of candidates has
been identiﬁed, including both new chemical entities and
compounds from existing drug classes. Examples of the
former include the nitroimidazole PA-824 [13,14], which
began Phase I trials in 2005, and the diarylquinoline R207910,
which was reported to yield complete culture conversion
within two months in an animal model when substituted into
existing drug combinations [15]. Examples of the latter
include moxiﬂoxacin and gatiﬂoxacin [16,17], already li-
censed for other indications.
In order to examine the expected beneﬁts of shortened
drug regimens, we developed a mathematical model of TB to
gain general insights into the impact of treatment duration
on TB dynamics, and to simulate various possible trajectories
of the epidemic under continued application of existing
tools, or addition of new technologies that may be developed
in the future. To provide a speciﬁc regional example, we
calibrated the model to epidemiologic data for WHO’s South-
East Asia region, which includes ﬁve of the 22 highest-burden
countries and accounted for approximately one-third of the
estimated TB cases and deaths in 2003 [1].
Methods
Basic Model
We developed a dynamic compartmental model of TB
(Figure S1), expanding on previous models that have been
used to examine the natural transmission dynamics of TB and
to evaluate alternative TB control strategies [18–21]. In
particular, we adapted the model presented by Dye et al.
[18] and preserved a number of key assumptions from that
model in order to build on their previous analysis of the
potential impact of DOTS with currently available regimens.
Mathematical details of the model and values for key
parameters relating to the transmission and natural history
of TB are presented in Protocol S1.
The model includes acquisition of infection, progression to
active pulmonary TB, diagnosis, and treatment. New in-
fections may lead to primary progression or to latent
infection, which is subject to endogenous reactivation or
exogenous reinfection. A previous infection is assumed to
confer partial immunity against reinfection.
Active pulmonary TB is categorized as smear-positive or
smear-negative, which are associated with different degrees of
infectiousness, different natural history parameters (govern-
ing spontaneous cure and TB fatality), and different treat-
ment outcomes. Untreated active cases may spontaneously
resolve and return to latent infection. A fraction of new
active cases are eligible for detection at a rate that reﬂects the
delay from disease onset to diagnosis. Both the proportion
eligible for detection and the detection rate may vary
between smear-negative and smear-positive cases.
We elaborated on previous models by explicitly tracking
the duration of treatment in months, in order to examine the
impact of shorter drug regimens. Patients who complete
treatment successfully are considered cured but remain
partially susceptible to reinfection. Those who discontinue
treatment early (default) or fail upon completion of treat-
ment face the same mortality risks as those without active
disease, but are partially infectious and subject to relapse to
active disease. Although relapsing cases may be detected and
treated again, we did not explicitly track treatment history
nor explicitly model distinct retreatment regimens.
Treatment Duration and TB Dynamics
To gain general insights into the relationships between
treatment duration and TB dynamics, we ﬁrst modeled the
introduction of treatment into a stable equilibrium, following
the example of Dye and colleagues [18]. We undertook a
range of different simulations, varying key parameters
relating to treatment programs, including duration, default
rates, and the probability of remaining infectious after
treatment failure. Considering treatment regimens of 2-, 4-,
and 6-mo durations, we estimated the fatality probability for
a treated case; the average cumulative duration of infectious-
ness for a new case of smear-positive TB; the number of
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case; and changes in annual incidence rates after introduc-
tion of treatment into steady-state conditions. Details on the
calculations supporting the estimation of each of these
quantities are reported in Protocol S1.
Expanded Model and Calibration to South-East Asia
To consider key features of TB epidemics in speciﬁc
current settings, we expanded the basic model to allow for
heterogeneous treatment, development of drug resistance,
and interactions between TB and HIV (see Protocol S1).
The model accommodates two different varieties of treat-
ment, for example representing DOTS and other programs,
with allowance for different trends in coverage over time and
different treatment outcomes.
We allowed for development of drug resistance through
poor treatment as well as transmission of resistant strains.
Although various proﬁles of drug resistance appear in
different settings [6], for parsimony we distinguished only
cases that are multidrug resistant—deﬁned by resistance to
the two most potent ﬁrst-line anti-TB agents (isoniazid and
rifampicin). We also incorporate a simpliﬁed model of HIV-1,
distinguishing between those who are infected and those who
are not. Incidence rates of HIV infection over time are taken
from WHO/UNAIDS estimates, with a three-year delay to
capture the decline in immune function relevant to TB
natural history (see Protocol S1). These additional details are
included in order to allow more realistic modeling of the
dynamics of real-world TB epidemics, and are reﬂected in the
results we present here; however, speciﬁc comment on
features of shorter drug regimens in relation to multidrug
resistance or HIV status is beyond the scope of this report.
Parameters in the model were calibrated to provide a close
ﬁt to estimated TB incidence and mortality in WHO’s South-
East Asia region, which includes India, Indonesia, Bangladesh,
Myanmar, and Thailand among the 22 highest-burden
countries. Calibration was undertaken in three stages. First,
we simulated a natural history TB epidemic until a stable
equilibrium was attained. This equilibrium was the same as
that used in the general analyses of treatment duration and
disease dynamics described above. Second, we introduced
treatment representing the beginning of national TB control
programs in countries such as India starting in the 1960s [22].
Third, we modeled the initiation of DOTS in the 1990s based
on reported program data on coverage and treatment
outcomes. Epidemiologic indicators for the South-East Asia
region were obtained from routine surveillance estimates by
WHO [1]. Treatment patterns and results were based on
reports from national TB control programs (see Figure S2
and Protocol S1) [1].
Scenario Analyses
Different scenarios were deﬁned to include alternative
assumptions about case detection coverage, cure rates, and
the introduction of new, shorter drug regimens. Alternative
scenarios relating to continued progress in scaling up DOTS
were modeled with a starting date of 2002, and introduction of
new drug regimens was modeled with a starting date of 2012.
Baseline Scenarios
We considered two different scenarios relating to con-
tinued application of DOTS with current regimens. The
scenarios, reﬂecting different case-detection probabilities,
are deﬁned in the model by varying the proportion of new
cases eligible for detection under DOTS and non-DOTS
programs (see Figure S2). For ease of practical implementa-
tion this parameterization of case detection in the model
departs slightly from the case detection statistics reported by
WHO (number of new cases detected divided by estimated
incident cases in a given year) but will approximate the
reported case detection ratio when trends in incidence and
coverage are relatively steady.
In the stable-DOTS scenario, scale-up of DOTS follows
reported trends through 2003 but stabilizes at the 2003 level
(with around 42% case detection coverage for new smear-
positive pulmonary cases). In the DOTS-target scenario, we
assumed that the WHO target of 70% case detection is
attained by 2009. Following Dye et al. [18], we assumed in
both the stable-DOTS and DOTS-target scenarios that
detection of smear-negative TB cases occurs in constant
proportion (60%) to detection of smear-positives.
New Drug Scenarios
To analyze the possible impact of new, shorter drug
regimens, we considered the beneﬁts of a 2-mo regimen,
including in the ﬁrst instance only the reductions in the
cumulative probability of default that would be attributable
to earlier treatment completion. We assumed that with either
current regimens or new, shorter regimens, monthly default
rates are 1.5% in DOTS treatment programs and 7.5% in
non-DOTS treatment programs, and that failure probabilities
for those completing a full treatment regimen are 3% in
DOTS programs and 6% in non-DOTS programs. Combined
with mortality risks, these assumptions translate into overall
cure probabilities for current regimens of 85% in DOTS
treatment programs and 50% in non-DOTS programs,
consistent with assumptions reported for this region by Dye
et al. [18]. For shorter regimens, the same monthly default
assumptions and failure probabilities applied over two
months yield cure probabilities of 93% and 80% in DOTS
and non-DOTS programs, respectively.
As an alternative set of scenarios relating to introduction
of new drug regimens, we further considered the potential for
shorter drug regimens to be accompanied by broader case
detection through the freeing of scarce ﬁnancial and human
resources and the lowering of barriers to initiation of
therapy. These additional beneﬁts are not certain to arise,
but their likelihood would be enhanced by development of
new diagnostic technologies. Speciﬁcally, we examined the
potential incremental beneﬁts that would be gained if the
proportion of undetected cases were reduced by half after
introduction of new drugs.
Sensitivity and Uncertainty Analysis
Uncertain model parameters were varied in sensitivity
analyses, and uncertainty analyses were conducted in order to
provide ranges around model outputs. We used a multiple
simulation approach in which parameter values were sampled
from deﬁned ranges and the model was recalculated under
each set of sampled parameter values. Sensitivity analysis was
used to identify those parameters that had the greatest
impact on the outcomes of interest. Ranges around estimates
are reported based on the 2.5th and 97.5th percentiles across
the set of simulations (see Protocol S1).
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General Implications of Treatment Duration
We ﬁrst evaluated the general relationship between treat-
ment duration and TB dynamics by simulating the introduc-
tion of treatment into a steady-state equilibrium, following
Dye and colleagues [18]. To identify an upper bound on the
beneﬁts of treatment, we modeled complete coverage in the
population and assumed (as in [18]) that scale-up of treatment
occurs in just one year. In this preliminary analysis, we
considered only treatment of smear-positive pulmonary
cases.
The beneﬁts of shortening regimens are best understood by
examining both direct impacts on improved treatment
outcomes due to accelerated treatment completion, and
indirect beneﬁts of reducing transmission due to shortened
average duration of infectiousness for treated cases. Figure 1
compares the implications of treatment regimens with
different durations and default rates, with respect to three
different indicators: (1) the average cumulative duration of
infectiousness for a smear-positive case, accounting for the
potential for multiple cycles of active disease, treatment, and
relapse; (2) the expected number of secondary infectious
cases generated by the average infectious case (effective
reproductive number), measured at 20 years after the
introduction of treatment; and (3) the mean annual rate of
decline in the incidence of active TB, computed for each year
relative to the previous year and then averaged over the 20
years following treatment introduction.
The beneﬁts of shortening the duration of therapy are
greatest when default rates are highest. With a monthly
default rate of 15%, for example, the expected cure rates for
regimens of 6, 4, and 2 mo would be approximately 40%,
50%, and 70%, respectively. Under these circumstances,
average declines in incidence would be three times higher for
a 4-mo regimen compared to a 6-mo regimen (adding around
4% to the average annual rate of decline in absolute terms),
and six times higher for a 2-mo versus a 6-mo regimen
(speeding declines by around 10% in absolute terms).
However, even at relatively low default rates, shorter
regimens are expected to enhance the epidemiologic impact
of therapy. For example, with a default rate of 3% per
month—implying an 80% cure probability for a 6-mo
regimen—the average annual rate of decline in incidence
would be 8% greater for a 4-mo regimen, or 14% greater for
a 2-mo regimen, compared to a 6-mo regimen (1% or 2%
increases, respectively, in absolute terms).
A critical reason that treatment default leads to poorer
epidemiologic outcomes is that incomplete treatment may
reduce mortality rates without eliminating infectiousness. In
our base scenario analyses (Figure 1), we assumed that 50% of
people who default from treatment would remain infectious,
but this assumption remains uncertain. We therefore
examined alternative assumptions in sensitivity analyses
(Figure S3). If only 25% of people who default from
treatment remain infectious, the beneﬁts of shortening
regimens from 6 mo to 2 mo would be marginally lower; for
example, at a monthly default rate of 15%, the absolute
difference in the pace of incidence decline under the shorter
regimens would be around 7% rather than 10%. If 75% of
defaulters remain infectious, on the other hand, beneﬁts of
shorter regimens would be even greater—with declines
around 12% faster in absolute terms for a 2-mo regimen,
assuming a monthly default rate of 15%.
The total impact of treatment on mortality includes both
direct beneﬁts to those persons who are treated and further
reductions in overall mortality due indirectly to reduced
incidence (Figure 2). In general, the proportion of the total
mortality reduction that is attributable to direct beneﬁts of
treatment rises as default rates rise (and hence cure rates fall),
since mortality beneﬁts attenuate less than transmission
beneﬁts under incomplete treatment. Mortality reductions
under shorter regimens are less sensitive to the default rate,
as expected, because opportunities for default are reduced as
treatment duration is shortened.
Scenario Analyses in South-East Asia
To examine the potential impact of new drugs in a
particular epidemiologic setting, we calibrated the model to
data for the South-East Asia region. Two different baseline
scenarios represented alternative trajectories in the scale-up
Figure 1. Impact of Treatment Duration on TB Dynamics
The horizontal axis in each plot shows monthly default rates, and the
three lines represent treatment durations of 6 mo (solid black line), 4 mo
(solid grey line), and 2 mo (dashed black line). The three panels show
model estimates for: (top graph) the average cumulative duration of
infectiousness for a smear-positive case; (middle graph) the effective
reproductive number measured 20 years after treatment is introduced;
and (bottom graph) the annual rate of decline in the incidence of active
TB, averaged over the 20 years following treatment introduction.
DOI: 10.1371/journal.pmed.0030273.g001
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continues at current levels (stable-DOTS baseline), the
numbers of new TB cases in the South-East Asia region are
expected to decline by an average of 2.1% (range 0.0%–3.2%)
per year over the period 2005 to 2030, with similar declines
(2.6% per year, range 0.0%–3.8%) expected for deaths. If the
WHO target of detecting 70% of new smear-positive TB cases
is reached by 2009 (DOTS-target baseline), cases and deaths
would decline by an average of 4.3% (range 1.3%–6.1%) and
5.1% (range 1.2%–6.8%) per year, respectively, over this
period (Figure 3). Under these two alternative baseline
scenarios the total numbers of cases and deaths over this
period would be, respectively, around 50 million and 20
million in the stable-DOTS scenario, or around 30 million
and 10 million in the DOTS-target scenario.
The potential impact ofnew drugs was examined in termsof
reductions in TB incidence and mortality through 2030,
including intermediate outcomes by the year 2015, of
relevance to the Millennium Development Goals. We com-
pared a variety of different measures across scenarios to
evaluate the beneﬁts of shorter regimens: incidence and
mortality rates in the years 2015 and 2030; annual rates of
declineinincidence andmortality(computedineachyear and
then averaged over the period 2012 to 2030); and cumulative
numbers of new cases and deaths between 2012 and 2030.
With the availability of a new 2-mo regimen starting in
2012, accounting only for the beneﬁts associated with earlier
treatment completion, annual incidence would be 9% (range
5%–11%) lower in 2015 and 39% (range 22%–51%) lower in
2030 than in the baseline stable-DOTS scenario. Annual
mortality reductions would be similar (11%, range 7%–13%;
and 46%, range 32%–54%, in 2015 and 2030, respectively).
Introduction of a shorter regimen would produce more than
a 2-fold increase in the rates of decline in incidence and
mortality compared to the stable-DOTS baseline (Figure 3).
Figure 2. Direct and Indirect Reductions in Mortality in Relation to
Treatment Duration and Monthly Default Rates
Each bar shows the total reduction in deaths over a 20-year period
following treatment introduction, expressed as a percentage of the
deaths expected in a steady-state, no treatment counterfactual. The blue
area in each bar indicates the reduction that is attributable directly to
benefits in treated patients.
DOI: 10.1371/journal.pmed.0030273.g002
Figure 3. Projected Trends in New TB Cases and Deaths in the WHO South-East Asia Region, 2005–2030
(A) Benefits of new drugs and enhanced detection are projected in comparison to the stable-DOTS baseline (constant 42% case detection).
(B) The same benefits as in (A) are projected in comparison to the DOTS-target baseline (70% case detection by 2009).
DOI: 10.1371/journal.pmed.0030273.g003
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cases and deaths in this region between 2012 and 2030 by
more than one-ﬁfth (Table 1).
If WHO case detection targets for DOTS are attained by
2009, introduction of a 2-mo regimen would reduce annual
incidence by 6% (range 3%–8%) by 2015 and 24% (range
13%–41%) by 2030. Annual mortality rates would be 10%
(range 7%–12%) lower in 2015 and 35% (range 25%–46%)
lower in 2030. The rates of decline in incidence would be
approximately one-third greater with new drugs than in the
DOTS-target baseline, and rates of decline in mortality would
be 45% greater with shorter regimens. Overall, the total
reductions in new cases and deaths through 2030 would be
approximately 13% (range 8%–19%) and 19% (range 15%–
23%), respectively, of the 2012–2030 totals (Table 1).
We also considered the possibility that availability of
shorter regimens, perhaps in combination with new diag-
nostic technologies, could enhance case detection efforts by
reducing resource demands per treated patient, simplifying
infrastructure, monitoring, and administrative requirements,
and lowering patient-related barriers to initiating therapy. If
new drugs and diagnostics could reduce the number of
undetected cases by half, in addition to providing the beneﬁts
of earlier treatment completion as described above, the
reductions in annual incidence and mortality by 2030 would
be around 40%–50% percent greater; cumulative effects over
the period 2012–2030 would be around 60%–70% greater
(Table 1). The total effect of introducing shorter regimens,
including potential enhancements in case detection, would be
to accelerate the declines in incidence and mortality by a
factor of around three compared to the stable-DOTS base-
line, or by around 50% and 70%, respectively, compared to
the DOTS-target baseline.
Thus far—considering the potential epidemiologic beneﬁts
of a 2-mo regimen available by the year 2012—we ﬁnd that
the total beneﬁts through the year 2030 could be as high as 11
million cases and 5 million TB deaths averted in a scenario in
which new regimens are accompanied by enhanced case
detection, compared to the stable-DOTS baseline. We may
also examine a retrospective counterfactual involving earlier
availability of a shorter-regimen drug. If a new drug had been
available starting in the year 2002, the total beneﬁt by 2030
would be approximately double (Figure 4). On the other
hand, if we consider an alternative future scenario in which a
2-mo regimen becomes available only in 2022, this delay
would erase nearly three-fourths of the beneﬁts expected
from a 2012 debut (Figure 4).
Discussion
Our analysis of the potential beneﬁts of introducing a new,
shorter drug regimen for treating active TB indicates that the
impact of DOTS could be enhanced substantially with the
availability of new tools. By reducing opportunities for
default and failure, shorter regimens could lower annual
incidence and mortality by around 40% by the year 2030; the
Figure 4. Impact of Alternative Timing for the Introduction of Shorter Drug Regimens
The left graph shows projected new TB cases in the WHO South-East Asia region, while the right graph shows projected deaths. The blue area in each
graph represents the additional cases and deaths that would have been averted if a new drug had been available in 2002, compared to availability in
2012. The red area shows the additional cases and deaths that can be averted if the new regimen becomes available in 2012 compared to 2022.
DOI: 10.1371/journal.pmed.0030273.g004
Table 1. Reductions in TB Incidence and Mortality
Comparison Scenario Annual TB
Incidence
in 2030
Annual TB
Mortality
in 2030
Cumulative
TB Incidence,
2012–2030
Cumulative
TB Mortality,
2012–2030
Compared to stable-DOTS baseline Earlier treatment completion only 39 (23–51) 46 (32–54) 21 (13–28) 25 (19–29)
Earlier completion plus enhanced detection 55 (35–70) 65 (49–74) 34 (23–43) 41 (34–46)
Compared to DOTS-target baseline Earlier treatment completion only 24 (13–41) 35 (25–46) 13 (8–19) 19 (15–23)
Earlier completion plus enhanced detection 35 (21–59) 51 (39–65) 22 (14–31) 31 (26–36)
Values are percent reductions (range) in annual and cumulative incidence and mortality by the year 2030 through introduction of a novel, 2-mo TB regimen.
DOI: 10.1371/journal.pmed.0030273.t001
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diagnostics could facilitate broader case detection in DOTS
programs would magnify these beneﬁts signiﬁcantly. We
recognize, however, that introduction of shorter regimens
will not automatically be accompanied by expanded case
detection—and that various elements in a global TB control
strategy must compete for scarce resources—so we emphasize
that these results are simply suggestive of additional beneﬁts
that might be realized through a wider reach of case
detection.
It is important to note that we have focused in this study on
the example of South-East Asia, where current cure rates in
DOTS programs are high, and where DOTS scale-up is
proceeding relatively quickly. The TB control target arising
from the Millennium Development Goals is likely to be met in
this region even without the introduction of new drugs. The
potential beneﬁts of shorter drug regimens described in this
report may therefore be considerably lower than those in
other regions where case detection in DOTS remains
minimal, or where cure rates are lower. Particularly in
regions where the pace of uptake of DOTS has been slow, the
potential for shorter drug regimens to lower barriers to
DOTS expansion could produce even greater beneﬁts than
those reported in our analysis.
Inevitably, a model requires a series of simplifying
assumptions that must be recognized. In particular, we have
modeled drug resistance and interactions with HIV in a
parsimonious fashion. The effect of a shorter regimen with
one or more new drugs may be particularly important in
settings where multidrug-resistant TB is highly prevalent, and
more subtle beneﬁts may be realized in relation to resistance
patterns other than multidrug-resistant TB. However, we
have not accounted for the possible development of
resistance to the new drugs. With regard to HIV, the relative
impact of new drugs in areas of high HIV prevalence remains
uncertain. More comprehensive conclusions about the range
of potential beneﬁts of new drug regimens in other regions
await ongoing analyses usinge x t e n s i o n so ft h em o d e l
described here.
Although we have indicated ranges around results that
reﬂect the imprecision in modeled outcomes that follows
from uncertain input parameters, these ranges do not
capture all sources of uncertainty. Certain elements of the
scenarios deﬁned here, such as the potential impact of new
drugs on case-detection coverage, are speculative, so results
should be interpreted as ‘‘what-if’’ assessments rather than as
ﬁrm predictions.
Nevertheless, several conclusions emerge from our analyses
as important inputs into ongoing policy discussions regarding
global TB control. We conﬁrmed that large potential gains
are expected if scale-up of DOTS proceeds rapidly. There is
likely to remain a substantial burden due to TB, however,
even under scenarios involving successful attainment of
coverage targets for DOTS. Incorporation of new technolo-
gies within the DOTS strategy could dramatically accelerate
the pace of declines in TB incidence and mortality expected
using current regimens—with up to 2- or 3-fold increases in
rates of decline if shorter regimens are accompanied by
enhanced case detection. Long-term strategies for reducing
the burden of disease from TB require a balanced approach
to pursuing new technologies while promoting wider imple-
mentation of proven strategies.
Supporting Information
Figure S1. Schematic of the Model
Notes: (1) Mortality rates are not shown. (2) Treated cases default and
move to treatment failure at rate dD or dN (speciﬁc to DOTS or non-
DOTS). A fraction (mD or mN) of cases completing the ﬁnal month of
treatment also fail. (3) A fraction (1mD or 1mN) of cases completing
the ﬁnal month of treatment are fully recovered. (4) Only detectable
cases are eligible to move from untreated to treated.
Found at DOI: 10.1371/journal.pmed.0030273.sg001 (21 KB PDF).
Figure S2. Case Detection Assumptions in Two Baseline Scenarios
Stable-DOTS scenario (left graph) assumes that detection of new
smear-positive cases in DOTS areas remains stable at 42% starting in
2003. DOTS-target scenario (right graph) assumes that DOTS
coverage reaches 70% by 2009.
Found at DOI: 10.1371/journal.pmed.0030273.sg002 (14 KB PDF).
Figure S3. Treatment Duration and TB Dynamics: Sensitivity Analysis
Graphs show the sensitivity of results in Figure 1 to the level of
infectiousness after incomplete treatment. The series of graphs on
the left assume that 25%, and the series on the right assume that 75%,
of defaulters remain infectious. In each series, the three graphs show
model estimates for: (top) the average cumulative duration of
infectiousness for a smear-positive case; (middle) the effective
reproductive number measured 20 years after treatment is intro-
duced; and (bottom) the annual rate of decline in the incidence of
active TB, averaged over the 20 years following treatment introduc-
tion. The horizontal axis in each plot shows monthly default rates,
and the three lines represent treatment durations of 6 mo (solid black
line), 4 mo (solid grey line), and 2 mo (dashed black line).
Found at DOI: 10.1371/journal.pmed.0030273.sg003 (13 KB PDF).
Protocol S1. Technical Appendix
Found at DOI: 10.1371/journal.pmed.0030273.sd001 (209 KB PDF).
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Editors’ Summary
Background. One third of the world’s population is infected with
Mycobacterium tuberculosis, the bacterium that is the main cause of
tuberculosis (TB). In most people, the infection remains dormant, but
every year eight million people develop active TB, usually in their lungs,
and two million people die from the disease. For most of the second half
of the 20th century, TB was in decline, particularly in developed
countries, due to the availability of powerful antibiotics. Recently,
however, global efforts to control TB have been set back by the HIV/AIDS
epidemic—people with damaged immune systems are very susceptible
to TB—and the emergence of antibiotic-resistant bacteria. In the 1990s,
the World Health Organization (WHO) introduced DOTS as the
recommended strategy for global TB control. Central to DOTS is ‘‘directly
observed short-course chemotherapy.’’ To cure TB, several antibiotics
have to be taken daily for 6 months. Patients must complete this
treatment, even if they feel better sooner, to prevent relapse and the
emergence of drug-resistant bacteria. The DOTS approach ensures that
patients do this by having trained observers watch them swallow each
dose of their medication for the entire 6-month period.
Why Was This Study Done? This year, WHO and partners launched a
renewed Global Plan to Stop TB, which aims to reduce, by 2015, the
number of people who are sick with TB (disease prevalence) and the
number of people who die each year from the disease (mortality) to half
the 1990 levels. Because sick people often infect others, reducing disease
prevalence will also reduce the number of new infections each year
(disease incidence). The Global Plan to Stop TB includes a commitment
to expand and intensify the DOTS strategy (in the year 2004, only around
half of new active, infectious TB cases were detected under DOTS). The
drug combinations currently used for DOTS consist of four or more
different antibiotics, which have all been around and in use for many
years. Recently, renewed effort has gone into the search for new TB
treatments. Several candidate drugs have been identified and are now
being tested, and scientists expect that some of them will be able to cure
patients quicker than the current 6-month regimen. In this study, the
researchers wanted to understand the potential benefits of such shorter
treatments.
What Did the Researchers Do and Find? The researchers developed a
mathematical model that considers the acquisition, progression,
diagnosis, and treatment of M. tuberculosis infection and its clinical
consequences. They used the model to predict how changes in
treatment duration might affect TB incidence, prevalence, and mortality.
In the model, shorter treatment durations are connected to higher cure
rates, as each additional month of treatment means more time to ensure
that patients keep taking their medications, and more doses that might
be missed. Since patients who drop out of treatment early can continue
to infect other people, the model shows how a 2-month course of
antibiotics will produce a quicker decline in the incidence of TB than a 6-
month course by reducing these opportunities to infect others.
The researchers then refined their model to include current
conditions in South-East Asia, an area where DOTS is being scaled up
and where one-third of all new TB cases occur. This ‘‘calibrated’’ model
indicates that even if DOTS is scaled up as planned, shorter drug courses
would still reduce TB incidence and deaths much quicker than a 6-month
course. If, for example, a 2-month drug treatment were introduced by
2012, it might prevent 13% of the new cases and 19% of the TB deaths
that would otherwise occur in South-East Asia between 2012 and 2030.
These benefits might be even greater if the new drug regimen freed up
resources to improve the systematic effort to detect new TB cases. On
the other hand, delaying its implementation until 2022 would erase
three-quarters of the predicted benefits.
What Do These Findings Mean? Like all mathematical models, this one
makes many assumptions that, if incorrect, will change the predictions.
With this caveat, the study confirms that the planned scale-up of DOTS
will greatly reduce TB incidence and mortality over the next few years.
However, it also suggests that the impact of DOTS could be substantially
improved by introducing shorter drug regimens. The earlier such shorter
treatments become available, the greater their benefits would be. By
reducing the opportunities for patients to default on their treatment and
by shortening the period during which they can infect others, the
researchers predict that the rate of decline in TB incidence and mortality
could be up to three times higher for antibiotics that only have to be
taken for 2 months compared with those that need to be taken for 6
months. But, they stress, strategies for reducing the global TB burden
must strike a balance between pursuing new treatment and detection
strategies and promoting wider implementation of proven strategies.
And while there is hope that new shorter treatments will prove effective
over the next few years, this will only become clear as candidates are
rigorously tested.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030273.
 US National Institute of Allergy and Infectious Diseases patient fact
sheet on TB
 US Centers for Disease Control and Prevention information for patients
and professionals on TB
 MedlinePlus encyclopedia entry on TB
 NHS Direct Online patient information on TB from the UK National
Health Service
 World Health Organization information on global TB control
 Global Alliance for TB Drug Development information on current
initiatives to develop new TB drugs
 Wikipedia page on TB treatment (note that Wikipedia is a free online
encyclopedia that anyone can edit)
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